Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors [RNA-Seq]
RNA-seq (gene expression) · human · 10 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 10 samples: 5 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumorsCell reports. Medicine · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE293843_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1246577 and SRA study SRP576518. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 10 samples.
How we read this: 5 replicated groups read from 10 sample titles; they account for 10 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8891598 QGP1_sgNC_Rep1 QGP1_sgNC
- GSM8891599 QGP1_sgNC_Rep2 QGP1_sgNC
- GSM8891600 QGP1_sgPIKFYVE_1_Rep1 QGP1_sgPIKFYVE_1
- GSM8891601 QGP1_sgPIKFYVE_1_Rep2 QGP1_sgPIKFYVE_1
- GSM8891602 QGP1_DMSO_Rep1 QGP1_DMSO
- GSM8891603 QGP1_DMSO_Rep2 QGP1_DMSO
- GSM8891604 QGP1_Torin1_Rep1 QGP1_Torin1
- GSM8891605 QGP1_Torin1_Rep2 QGP1_Torin1
- GSM8891606 QGP1_Apilimod_Rep1 QGP1_Apilimod
- GSM8891607 QGP1_Apilimod_Rep2 QGP1_Apilimod
- GSE295392 PIKfyve-regulated lipid metabolism as a therapeutic vulnerability in neuroendocrine prostate cancer 82 samples shares neuroendocrine, vulnerability, therapeutic
- GSE285592 Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers [RNA-seq] 18 samples shares vulnerability, therapeutic, rna-seq
- GSE275636 ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma [PDX RNA-seq] 10 samples shares vulnerability, therapeutic, rna-seq
- GSE216054 DNA methylation as a therapeutic target in RB1 deficient and neuroendocrine prostate cancer and rational co-targeting with B7-H3 31 samples shares neuroendocrine, therapeutic, targeting
- GSE336720 DNMT3B plays antagonistic roles with SMARCB1 and is a targetable vulnerability in rhabdoid tumors [RNA-seq] 68 samples shares vulnerability, rna-seq
- GSE302078 The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies 56 samples shares vulnerability, therapeutic
- GSE275637 ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma 50 samples shares vulnerability, therapeutic
- GSE273492 Selective NSD2 Inhibition Reveals an Epigenetic Vulnerability of KRAS-Driven Cancers [RNA-Seq] 36 samples shares vulnerability, rna-seq
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.